25 results
Thumbnail

D3.278 - Cold urticaria: a case report

Thumbnail

D3.279 - Biomarkers in anaphylaxis

Thumbnail

D3.282 - Anaphylaxis to Gadoteric Acid: A Case Report

Thumbnail

D3.283 - Taming the Unpredictable: Omalizumab’s Role in Idiopathic anaphylaxis and chronic spontaneous urticaria

Thumbnail

D3.284 - Update of the Brazilian Anaphylaxis Registry

Thumbnail

D3.285 - Improving Emergency Department Management of Adult Anaphylaxis: A Quality Improvement Initiative

Thumbnail

D3.286 - Rapid Symptom Resolution in Oral Allergy Syndrome Following Anaphylm Administration: A Phase 2 Study Update

Thumbnail

D3.287 - Adverse reactions and complications of Allergic Skin Test (SPT) in North Indian population

Thumbnail

D3.288 - Asthma and Anaphylaxis Induced by Milk with NSAID as a Cofactor in Adult Patient Sensitized to Dairy Proteins Due to Environmental Exposure in a Dairy Farm

Thumbnail

D3.289 - Pharmacokinetics of adrenaline administered via the ZiBiPen: First human trial findings

Thumbnail

D1.309 - Association of Antenatal Corticosteroids with Risk of Autoimmune Diseases in Children: a Nationwide Cohort Study

Thumbnail

D1.308 - Case report: challenges in a long-term prophylaxis in hereditary angioedema (HAE)

Thumbnail

D1.310 - Phenotypes of patients with Hereditary Angioedema (HAE): a case series

Thumbnail

D1.311 - Treatment Dilemmas in CARMIL2 Deficiency

Thumbnail

D1.312 - Acquired C1-inhibitor deficiency angioedema treated with lanadelumab: a case series

Thumbnail

D1.313 - Inborn Error of Immunity Associated Inflammatory Bowel Disease at a Tertiary Care Center

Thumbnail

D1.315 - Classifying the unclassifiable: diagnosis, characterization, and management of adults with unclassified primary antibody deficiency (unPAD)

Thumbnail

D1.316 - Lessons Learned from the Diagnosis and Management of a female pediatric patient with NCF2 Mutations and Chronic Granulomatous Disease

Thumbnail

D1.317 - A Retrospective Analysis of Dengue-Associated Hemophagocytic Lymphohistiocytosis in a Dengue-Endemic Country

Thumbnail

D1.318 - Extending Lanadelumab Dosing Intervals to Every 4 Weeks With Sustained Effectiveness for Hereditary Angioedema Attack Prevention: An Analysis From the Final ENABLE Study Data